

Recommendations for Vaccination in Adult Patients with Systemic Inflammatory Rheumatic Diseases from the Portuguese Society of Rheumatology

Cordeiro I¹, Duarte AC¹, Ferreira JF², Gonçalves MJ^{3,10}, Meirinhos T⁴, Rocha TM⁵, Romão VC^{3,10},
Sousa S¹, Guedes M⁶, Conde M⁷, Abreu C⁸, Aleixo MJ⁹, Santos MJ¹⁰

ACTA REUMATOL PORT. 2018;43:105-122 (SUP)

ABSTRACT

Background: Serious infections are a major cause of morbidity and mortality in systemic inflammatory rheumatic disease (SIRD) patients. Although vaccination may prevent numerous infections, vaccination uptake rates are low in this group of patients.

Objectives: To develop evidence-based recommendations for vaccination in SIRD patients.

Methods: We searched MEDLINE (until 31 October 2014) and EMBASE (until 14 December 2014) databases, as well as the ACR and EULAR congress abstracts (2011-2014). Patients with any systemic inflammatory rheumatic disease were included and all vaccines were considered. Any safety and efficacy outcomes were admitted. Search results were submitted to title and abstract selection, followed by detailed review of suitable studies. Data were subsequently pooled according to the type of vaccine and the SIRD considered. Results were presented and discussed by a multidisciplinary panel and systematic literature review (SLR)-derived recommendations were voted according to the Delphi method. The level of agreement among rheumatologists was assessed using an online survey.

Results: Eight general and seven vaccine-specific recommendations were formulated. Briefly, immunization status should routinely be assessed in all SIRD patients. The National Vaccination Program should be followed and some additional vaccines are recommended. To maximize the efficacy of vaccination, vaccines should preferably be administered 4 weeks before starting immunosuppression or, if possible when disease activity is controlled. Non-live vaccines are safe in SIRD, including immunosuppressed patients. The safety of live attenuated vaccines in immunosuppressed patients deserves further ascertainment, but might be considered in particular situations.

Discussion: The present recommendations combine scientific evidence with the multidisciplinary expertise of our taskforce panel and attained desirable agreement among Portuguese rheumatologists. Vaccination recommendations need to be updated on a regular basis, as more scientific data regarding vaccination efficacy and safety, emergent infectious threats, new vaccines as well as new immunomodulatory therapies become available.

Keywords: Antirheumatic agents; Immunosuppressive agents; Biological products; Rheumatic diseases; Vaccination; Recommendations

1. Rheumatology Department, Hospital Garcia de Orta, Almada;
2. Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra
3. Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa
4. Rheumatology Department, Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga, Aveiro
5. Rheumatology Department, Hospital de São João, Centro Hospitalar São João, Porto
6. Department of Pediatrics, Hospital Santo António, Centro Hospitalar do Porto, Porto
7. Pediatric Rheumatology Unit, Pediatrics Department, Hospital Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisboa
8. Infectious Diseases Department, Hospital de São João, Centro Hospitalar São João, Porto. Faculdade de Medicina do Porto, Portugal. Instituto de Inovação e Investigação em Saúde [I3S], Grupo de I&D em Nefrologia e Doenças Infeciosas, Instituto Nacional de Engenharia Biomédica [INEB], Porto, Portugal
9. Infectious Diseases Department, Hospital Garcia de Orta, Almada
10. Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisboa

INTRODUCTION

Patients with rheumatic diseases are at higher risk for infections, which contributes to increased morbidity and mortality¹⁻¹⁰. Several factors have been associated

with increased susceptibility to infections, including disease activity and medication, in particular immunosuppressants¹⁻¹⁰. Effective and safe vaccination is essential for the prevention of a significant number of these infections^{11,12}. However, vaccination uptake rates among rheumatic patients are remarkably low¹³⁻¹⁹. Over the years, several scientific societies have developed practice guidelines and/or recommendations aiming to provide guidance on the optimal use of vaccines and improve vaccination adherence among patients with rheumatic diseases²⁰⁻²³. According to these recommendations, non-live vaccines can be given safely to patients treated with immunomodulators. The major differences among guidelines concern the safe use of live attenuated vaccines, due to the scarcity of data.

We aimed to develop evidence-based recommendations for the vaccination of adult patients with systemic inflammatory rheumatic diseases (SIRD), with a particular focus on safety and efficacy of vaccination in immunosuppressed SIRD patients.

METHODS

We performed a comprehensive systematic literature review (SLR), addressing the safety and efficacy of vaccination in systemic inflammatory rheumatic diseases (SIRD). We searched MEDLINE (until 31 October 2014) and EMBASE (until 14 December 2014) databases. Additionally, we searched the abstracts of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) congresses (2011-2014) and performed a complementary hand search. Patients (both adults and children) with any SIRD were included and all vaccines were considered. Any safety and efficacy outcomes were admitted. Studies that assessed the simultaneous administration of two or more vaccines (except commercially available combinations), reviews and single case reports were excluded.

Title and abstract selection was performed by 8 independent reviewers. The selected studies were submitted to independent detailed review (view Figure 1). Translation was requested when needed. Study and patient characteristics, the use of glucocorticoids and immunosuppressants (both synthetic and biologic), type of vaccine, as well as safety and efficacy outcomes were independently extracted into piloted forms. Data were subsequently pooled according to the type of vac-

cine and the SIRD considered. The quality of individual studies was appraised using an adapted checklist of 13 items²⁴ (Appendix 1). Risk of bias was assessed using the Cochrane Collaboration Tool²⁵. Subsequently, a descriptive analysis was performed.

SLR results were presented and discussed at a national meeting (63 participants) by a multidisciplinary panel that included rheumatologists, infectious disease specialists, experts on immunization, health professionals and patients' representatives. The taskforce formulated eight general recommendations and seven vaccine-specific recommendations for adult patients with SIRD. Preliminary statements were afterwards submitted to the appraisal of the entire group and voted according to the Delphi method. A minimum concordance rate of 80% was considered necessary for the approval of each individual statement as a final recommendation. When below this level of agreement, the content and phrasing of each statement were discussed until a suitable concordance rate was attained. The agreement with the final set of recommendations was assessed using an online survey (52 participants); participants were asked to score their level of agreement with each recommendation using a 10-point quantitative scale (from 0-total disagreement to 10-total agreement).

RESULTS

We retrieved 14594 abstracts. After title and abstract selection, followed by the detailed review of the most relevant results, 123 papers were identified. We initially planned to issue recommendations for both adults and children with SIRD, but at the time of this study another working group was preparing recommendations for the pediatric population; therefore, 28 pediatric studies were additionally excluded and a final total of 95 articles concerning adults with SIRD were reviewed (Figure 1).

We obtained 65 papers on influenza vaccination²⁶⁻⁹¹, 20 on pneumococcal⁹²⁻¹¹², 4 on viral hepatitis¹¹³⁻¹¹⁶, 2 on varicella zoster vaccine¹¹⁷⁻¹¹⁹ and 4 papers on various other vaccines (including papillomavirus¹²⁰, poliomyelitis¹²¹, diphtheria/tetanus/pertussis (DTP)¹²² and yellow fever¹²³ vaccines). Studies focused on different SIRD, namely rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, psoriathic arthritis, primary systemic vasculitis, systemic sclerosis, polymyositis, Sjögren's syndrome, antiphospholipid




FIGURE 1. Search strategy for the systematic literature review

antibody syndrome and undifferentiated connective tissue disease. Table I summarizes the distribution of included studies according to the disease and vaccine considered.

RECOMMENDATIONS

Eight general principles and seven vaccine-specific recommendations were formulated, reaching a high level of agreement among Portuguese rheumatologists (Table II).

GENERAL PRINCIPLES

1. The initial assessment of all patients with systemic inflammatory rheumatic diseases (SIRD) should include immunization status and catch-up vaccination schedule, according to the National Vaccination Program, if necessary. Level of evidence¹²⁴ 2a; Grade of recommendation C; Agreement (mean and standard deviation (SD)): 9.4 (1.3).

Vaccination was proven to be safe and effective in

the prevention of many infectious diseases²⁶⁻¹²⁴. However, particular safety and efficacy issues must be taken into consideration when vaccinating SIRD patients, especially those on immunosuppressants^{30,31,36,38,93-95,98,101,102,109}. The taskforce considered that the vaccination status of all SIRD patients must ideally be assessed at the moment of diagnosis and always before starting immunosuppressive therapy.

2. Vaccines should be administered ideally at least 4 weeks before starting any immunosuppressive therapy and, when possible, disease activity should be controlled. Level of evidence 4; Grade of recommendation C; Agreement (mean (SD)): 8.5(1.9).

Early disease was considered a sensible time for vaccination, especially if live vaccines are considered. In general, vaccines are safe and effective, regardless of disease activity. A few studies included patients with active disease who were able to mount an adequate immune response and there was no consistent evidence that vaccines lead to an increased number of flares or

TABLE I. DISTRIBUTION OF THE INCLUDED STUDIES ACCORDING TO THE DISEASES AND VACCINES ASSESSED

Vaccine	RA	SLE	SpA/PsA	PSV	SSc/PM	Other
Influenza	25	23	8	10	9	7
Pneumococcus	9	9	3	–	–	1
Viral hepatitis	2	1	–	1	–	–
Varicella zoster	3	1	3	–	–	–
Papillomavirus	–	1	–	–	–	–
Polio (oral)	–	1	–	–	–	–
DTP/ Tetanus	1	1	–	–	–	–
Yellow fever	1	–	–	–	–	–

Please note that there is some overlap in the numbers because some studies included different SIRDs (≥ 1 patient) simultaneously. RA: Rheumatoid arthritis, SLE: systemic lupus erythematosus, SpA: spondyloarthritis, PsA: psoriathic arthritis, PSV: primary systemic vasculitis, SSc: systemic sclerosis, PM: polymyositis, JSIRD: juvenile systemic inflammatory rheumatic diseases, MMR - measles/mumps/rubella, DTP - diphtheria/tetanus/pertussis. Other diseases include: Sjögren's syndrome, antiphospholipid antibody syndrome, /undifferentiated connective tissue.

adverse effects^{47,51,52,70,71,74,96,99,100,104,107,120,124}. An exception was lower immunogenicity of influenza vaccination in SLE patients, a trait frequently related with disease activity⁴⁹. On the other hand, immunosuppressive therapies (conventional DMARDs, biologics and moderate to high doses of steroids) reduce the immunogenicity of non-live vaccines^{27,29,38,49,51,64,69,94,95,101,106,109,123}. The use of immunosuppression was very consistently associated with lower efficacy of influenza and pneumococcal vaccines in RA, SpA and CTD^{27,29,38,49,51,64,69,94,95,101,106,109}. This can reflect both a direct effect of the drugs and indirectly the effect of disease activity. Therefore, vaccines should preferably be administered to stable patients. Nonetheless, if stability cannot be achieved, it is safe to vaccinate and it should be done, as the risk of infection is likely to be increased in active SIRD^{125,126}.

3. Patients receiving Rituximab should ideally be vaccinated at least 4 weeks before the biological therapy is started. When this is not possible, vaccination should occur 6 months after the previous infusion (mean (SD)). Level of evidence 2a, Grade of recommendation B, Agreement: 8.8(1.4).

Rituximab is a chimeric IgG1CD20-specific monoclonal antibody that depletes peripheral blood B cells with subsequent reduction in differentiated plasma cells (responsible for immunoglobulin production). Patients receiving rituximab have an impaired response to inactivated or bacterial vaccines due to a reduction in protective antibodies^{64,70,100,88,89,127,128}. This is particularly evident with pneumococcal vaccines, either conjugated or polysaccharide, where treatment with rituxi-

mab is associated with significantly lower antibody response^{89,93,129}. In patients in whom vaccination is indicated, immunization should take place at least 4 weeks before drug administration. If a patient has already received rituximab, responses may be blunted at least until B cell recovery occurs, which takes between 6 to 9 months. Sometimes the ideal timing for vaccination cannot be accomplished, particularly in case of seasonal influenza, but in these situations the clinical benefit of vaccination still exists^{46,88,89,129}.

4. Post vaccination assessment of antibody titers is not routinely recommended except for hepatitis B. Level of evidence 5; Grade of recommendation D; Agreement (mean (SD)): 8.8(1.6).

In immunosuppressed patients, the response to hepatitis B immunization (measurement of anti-HBs titers) should be assessed 4 to 8 weeks after completion of the 3-dose schedule. A titer of anti-HBs above 10 IU/L should be considered protective. Titers of antibodies after measles, rubella, varicella, pertussis and mumps are neither reasonably specific nor sensitive. Pneumococcal, tetanus and influenza vaccines are acceptably effective in SIRD patients; therefore, we do not recommend the assessment of their post-vaccination titers in daily clinical practice.

5. Non-live vaccines can be safely administered during treatment with synthetic or biologic DMARDs. Level of evidence 1b, Grade of recommendation A; Agreement (mean (SD)): 9.3(1.0).

The efficacy and safety of several non-live vaccines

TABLE II. RECOMMENDATIONS FOR THE VACCINATION OF ADULT PATIENTS WITH SYSTEMIC INFLAMMATORY RHEUMATIC DISEASES

Recommendations	Level of evidence ¹²⁴	Grade	Agreement (0-10), mean(SD)
General			
The initial assessment of all patients with systemic inflammatory rheumatic diseases (SIRD) should include immunization status and catch-up vaccination schedule, according to the national vaccination program, if necessary.	2a	C	9.4 (1.3)
Vaccines should be administered ideally at least 4 weeks before starting any immunosuppressive therapy and, when possible, disease activity should be controlled.	4	C	8.5 (1.9)
Patients receiving rituximab should ideally be vaccinated at least 4 weeks before the biological therapy is started. When this is not possible, vaccination should occur 6 months after the previous infusion.	2a	B	8.8 (1.4)
Post vaccination assessment of antibody titers is not routinely recommended except for hepatitis B.	5	D	8.8 (1.6)
Non-live vaccines can be safely administered during treatment with synthetic or biologic DMARDs.	1b	A	9.3 (1.0)
Live attenuated vaccines may be considered for certain patients receiving immunosuppressive therapy.	4	D	7.9 (1.6)
Vaccination of close contacts should be strongly considered in certain situations, depending on patient characteristics, degree of immunosuppression and the infectious agent.	5	D	8.1 (2.0)
Patients with SIRD who wish to travel should attend a travel medicine consultation at least 6 months in advance.	2b	C	9.0 (1.6)
Specific			
Yearly anti-influenza vaccination is recommended to all patients with SIRD regardless of current therapy.	2c	B	8.7 (1.5)
Pneumococcal vaccination (PCV13 + PPSV23) is recommended for patients with iatrogenic immunosuppression, including systemic corticosteroids and synthetic or biologic DMARDs (*).	2b	B	9.0 (1.5)
The dosing schedule must take in consideration the patient's age and previous immunization.	2b	B	
All SIRD patients with negative serology for hepatitis B virus (HBsAg, AntiHBc, and AntiHBs negative) should be vaccinated.	2b	C	8.7 (1.4)
In the case of isolated AntiHBc antibody positivity and negative viral load, vaccination should be considered.	5	D	
The response to vaccination should be assessed 1-2 months after the third dose, and revaccination considered (0, 1 and 6 months) if seroprotection is not achieved.	2b	C	
Hepatitis A vaccination is recommended for SIRD patients travelling to endemic areas, preferably with 2 doses 6 months apart.	2b	B	8.9 (1.4)
Consider HPV vaccine with 3-dose series (0, 2 and 6 months) for young adults with SIRD if not vaccinated previously.	2b	C	8.6 (1.7)
Patients with SIRD should follow the recommended vaccination schedule in the national vaccine program for anti-tetanic, i.e., every 10 years.	2b	C	9.6 (1.0)
The individual assessment of the risk/benefit ratio of HZV is recommended for patients with SIRD who are 60 years of age and older.	4	D	8.7 (1.7)

(*) Systemic corticotherapy ≥ 20 mg/day prednisolone or equivalent for ≥ 14 days; methotrexate $> 0,4$ mg/Kg/week; azathioprine > 3 mg/Kg/day; leflunomide, mycophenolate, cyclophosphamide, cyclosporine and tacrolimus. Biological therapy or DMARDs used in rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome and inflammatory bowel disease, including anti-TNF (infliximab, etanercept, adalimumab, golimumab, certolizumab); anti-CD20 (rituximab); anti-IL6 (tocilizumab); CTLA-4-Ig (abatacept); anti-BLYS (belimumab); anti-IL12 e anti-IL23 (ustekinumab); IL-1 antagonist (anakinra/canakinumab).

in SIRD patients were assessed, namely influenza²⁹, pneumococcal⁶⁶, hepatitis A¹¹⁵, hepatitis B¹¹⁴, human papillomavirus vaccine¹²⁰ and tetanus toxoid¹⁴². Most studies assessed RA^{51,70} and SLE^{81,99} patients, with a lesser extent of patients with systemic sclerosis, spondyloarthritis and primary systemic vasculitis^{29,52}. The immunosuppressants considered included glucocorticoids^{87,101,110,120,127}, various synthetic disease-modifying antirheumatic drugs (sDMARD)^{69,101,110,120}, cyclophosphamide^{29,45,99,100}, tumour necrosis factor (TNF) blocking agents^{27,36,40,42,81-74,105}, rituximab^{30,39,69,88,89}, tocilizumab^{64,102,104}, abatacept^{59,60,104} and belimumab⁹¹. Although sufficiently powered studies are lacking, vaccination was globally safe. Most vaccine-related adverse events reported were mild local and systemic adverse events, apparently unrelated to either disease or immunosuppression. Serious adverse events were rare^{94,129} and were associated neither to vaccination nor to immunosuppression⁴⁴.

The vast majority of studies support the idea that vaccination with non-live vaccines is not significantly associated with clinical or laboratorial flares comparing to healthy controls^{70,81}.

Thus, the taskforce considers that vaccination with non-live vaccines can be safely administered during immunosuppressant treatment, including sDMARD, cyclophosphamide, TNF blockers, rituximab, tocilizumab, abatacept and belimumab.

6. Live attenuated vaccines may be considered for certain patients receiving immunosuppressive therapy.

Level of evidence 4, Grade of recommendation D, Agreement (mean (SD)): 7.9(1.6).

Live vaccines are prepared from live microorganisms or viruses cultured under adverse conditions, leading to loss of their virulence but maintenance of their ability to induce protective and long lasting immunity. The administration of live vaccines bears the potential risk of invasive infection in immunosuppressed patients. The risk of infection is higher in live vaccines with a high potential of replication (e.g. yellow fever vaccine) rather than in vaccines with a low risk of replication (typhoid oral vaccine, varicella/herpes zoster vaccine). In most international guidelines, live vaccines are contraindicated during treatment with immunosuppressants^{22,129-134}. Although sufficiently powered studies are lacking, there is growing evidence that live attenuated viral vaccines, such as live-attenuated influenza^{136,136}, varicella-zoster virus^{118,119}, MMR^{140,11,142} and yellow

fever virus¹²⁴ vaccines might actually be safe for immunosuppressed patients in well-defined situations.

Our taskforce considered that live attenuated vaccines may be used with caution in SIRD patients. If a live vaccine is indicated in a patient on immunosuppressive treatment, an individual assessment of the risk/benefit must be performed, which includes disease activity, medication, the replication potential of the vaccine and the risk of infection. The risk assessment by an infectious diseases or vaccination expert is encouraged.

7. Vaccination of close contacts should be strongly considered in certain situations, depending on patient characteristics, degree of immunosuppression and the infectious agent. Level of evidence 4, Grade of recommendation D, Agreement (mean (SD)): 8.1(2.0).

The aim of immunizing close contacts of SIRD patients is to counter the suboptimal immune responsiveness of immunosuppressed patients and to prevent the transmission of vaccine-preventable pathogens to these susceptible individuals¹³⁷. Close contacts of immunosuppressed* patients, as well as health professionals participating in the care of immunocompromised¹³⁸ individuals*, should be offered routine annual immunizations with inactivated influenza vaccine in order to minimize disease spread¹³⁹. Close contacts should also comply or catch-up with the recommended schedules for tetanus vaccination, pneumococcal, MMR and varicella zoster virus (VZV) vaccines^{140,141}. Limited data are available on the risk of immunosuppressed individuals acquiring infection from a family member or close contact who receives a live vaccine¹⁴⁰. Recent recommendations on primary immunodeficiency note that microorganism transmission from family contacts receiving vaccines is a rare but possible event¹⁴⁰. Oral live polio vaccine is contraindicated in immunocompromised patients^{142,143} and their household contacts¹⁴⁰. An immunocompromised individual without previous exposure to varicella zoster virus is at minimal risk of transmission from a close-contact recently immunized for VZV, unless blisters develop at the site of administration. In this case, isolation of the patient is recommended and varicella zoster immunoglobulin could be given prophylactically¹⁴⁰.

(*) Systemic corticotherapy ≥ 20 mg/day prednisolone or equivalent for ≥ 14 days; methotrexate $> 0,4$ mg/Kg/week; azathioprine > 3 mg/Kg/day; leflunomide, mycophenolate, cyclophosphamide, cyclosporine and tacrolimus. Biological

therapy or DMARDs used in rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome and inflammatory bowel disease, including anti-TNF (infliximab, etanercept, adalimumab, golimumab, certolizumab); anti-CD20 (rituximab); anti-IL6 (tocilizumab); CTLA-4-Ig (abatacept); anti-BLYS (belimumab); anti-IL12 e anti-IL23 (ustekinumab); IL-1 antagonist (anakinra/canakinumab).

8. Patients with SIRD who wish to travel should attend a travel medicine consultation at least 6 months in advance. Level of evidence 2; Grade of recommendation C; Agreement (mean (SD)): 9.0(1.6).

Immunocompromised individuals are at greater risk of contracting disease while travelling than healthy persons, particularly in destinations where several vaccine-preventable infections are endemic. Anticipated planning is crucial to safe and successful travelling. A pre-travel consultation with a travellers' health, infectious diseases, tropical medicine or vaccination expert is encouraged, so as to assess the risk of exposure to infections and other hazards during travel and to implement adequate preventive strategies. The consultation must be performed timely because patients may require destination, transportation or accommodation adjustments, catch-up and/or additional vaccination and also disease chemoprophylaxis¹³¹. The taskforce considered appropriate a minimum advance of 6-months to allow time for completion of most multiple-dose vaccination schemes. Inactivated vaccines can be safely administered to patients on immunosuppression (view General Recommendation 5). These vaccines include those against viral hepatitis A and B, Japanese encephalitis, tick borne encephalitis and rabies, as well as the inactivated form of the typhoid and polio vaccines (view Specific Recommendations). Specific vaccination and chemoprophylactic strategies, including the administration of live attenuated vaccines in this context, should be based on an individual risk-benefit assessment (view General Recommendation 6).

B. VACCINE-SPECIFIC RECOMMENDATIONS

1. Influenza

Yearly anti-influenza vaccination is recommended to all patients with SIRD regardless of current therapy. Level of evidence: 2c, Grade of recommendation: B; Agreement (mean (SD)): 8.7(1.5).

EFFICACY

Acute lower respiratory infections are a significant concern in SIRD patients¹⁴⁴⁻¹⁴⁶. Multiple cohort studies assessed the vaccine immunogenicity in different SIRD, comparing the efficacy of the vaccine in patients under different therapies or versus healthy controls. Most

studies indicate preserved immunogenicity to the influenza vaccine in SIRD*.

Rheumatoid arthritis. Influenza vaccination in RA patients was proven globally effective and leads to a reduction in respiratory infections³⁷. It was suggested that male gender, old age and smoking were related to worse vaccine responses^{37,95,64}. Treatment with methotrexate (MTX), leflunomide and TNF inhibitors was also associated with lower efficacy, but reasonable values of seroprotection (SP) were obtained in the majority of studies (SP>60-70%)^{26,36,38,40,47,51,70,73-75}. Impairment of the vaccine immunogenicity was more significant in patients on rituximab and abatacept (seroconversion (SC) 10-40%)^{36,46,59,64,65,85}. Data on tocilizumab (TCZ) are scarce, but one study showed that patients under TCZ monotherapy have a better response to the vaccine in comparison with patients treated with the association TCZ+MTX⁵⁴.

Spondyloarthritis (SpA). In general, H1N1 vaccination induced a protective response in SpA patients (SP>60-70%). One sole study used the seasonal influenza vaccine, also with reasonable efficacy. There was a tendency for better responses in SpA patients when compared with RA patients. Within SpA patients, better responses were observed in Ankylosing Spondylitis (AS) versus Psoriatic Arthritis (PsA). Most studies suggest that TNF inhibitors reduce the vaccine responses. Older age (>60 years-old), smoking and methotrexate treatment were also associated with lower efficacy^{27,29,52,55,64,73,74,95}.

Connective tissue diseases (CTD) and primary systemic vasculitis (PSV). Influenza vaccination was less effective in SLE patients than in healthy controls. Nonetheless, in a majority of studies, seroprotection rate was close to 70%^{49,52,69,71,72}. Steroid use (prednisolone in doses above 10-20mg) and treatment with other immunosuppressants (azathioprine, mycophenolate, etc.) were associated with lower efficacy^{69,71,80,91}. Hydroxychloroquine might restore the immunogenicity in patients on immunosuppressants⁷¹. In a sub-analysis of the BLISS trial, patients on belimumab maintained the seroprotection over time likewise patients on placebo⁹¹. Furthermore, newly vaccinated patients during the trial had good vaccine responses independently of the treatment group. In a heterogeneous group of 16 CTD patients treated with rituximab, the seroprotection was not achieved in about half of cases³⁹. Data concerning other CTDs, including PSV are considerably limited. However, data point to a similar efficacy to that observed in SLE patients^{45,52,64}.

SAFETY

Safety outcomes included all adverse events (including local and systemic effects), disease activity scores and autoantibody measurements in a variable time period after the vaccine administration.

RA. The influenza vaccine exhibited an excellent safety profile, in spite of past or present therapy. No serious adverse events were reported. Mild local reactions and flu-like symptoms were described in slightly higher frequencies of those observed in healthy population. Five studies reported elevation of disease activity after vaccine administration, but this result was contradicted in twelve other studies^{22,26,28,29,46,47,50-52,54,59,60,64,65,70,72-75,77}.

SpA. Safety issues were poorly described, as no studies specified the occurrence of adverse events. Vaccination does not seem to influence disease activity^{27,29,36,52,55,64,73,74}.

CTD and PSV. Vaccination in SLE patients is generally safe. Mild adverse events (local reaction and flu-like syndromes) occurred with variable frequency (5-41%). In all 17 studies which addressed safety issues, two serious events were reported (an acute myocardial infarction and a deep venous thrombosis), that were not considered to have a causal relationship with the vaccine. Some studies report a transitory rise in auto-antibody titers^{40,43,44,49,61,63,69,71,78-80,87,90,91}. Vaccination does not seem to influence disease activity^{27,29,36,52,55,64,73,74}.

There are conflicting results on the frequency of flares after vaccination, though eight out of twelve studies did not show an increased frequency of flares.

(*) European Guidelines propose that an efficacious influenza vaccine should confer a seroprotection (SP) rate >70% or a seroconversion (SC) rate >40% in adults between 18 and 60 years-old¹⁴⁸.

2. PNEUMOCOCCAL

a) 23-valent Pneumococcal polysaccharide vaccine (VPP23) and 13-valent Pneumococcal conjugate vaccine (VPC13) are recommended in patients with iatrogenic immunosuppression, including systemic corticosteroids and synthetic or biological Disease-Modifying Antirheumatic Drugs (DMARDs)* Level of evidence 2b, Grade of recommendation B.

b) Schedule for pneumococcal vaccination must take into consideration patient's age and previous immunization status. Level of evidence 2b, Grade of recommendation B.

Agreement (all statements, mean (SD)): 9.0(1.5).

INDICATIONS

Streptococcus pneumoniae infection is responsible for

substantial mortality and morbidity in elderly adults (aged ≥ 65 years) or with underlying chronic or immunosuppressive conditions¹⁴⁸⁻¹⁵⁰. Vaccination plays a crucial role in protection from infections caused by these bacteria¹⁵⁰. At the moment, 2 pneumococcal vaccines are available: 23-valent polysaccharide vaccine (VPP23) and 13-valent conjugate vaccine (VPC13). VPP23 induces antibodies primarily by T-cell-independent mechanisms, therefore without development of immunological memory¹⁵¹. The levels of antibodies directed to most pneumococcal vaccine antigens remain elevated for at least 5 years and decrease progressively to prevaccination levels within 10 years. A more rapid decline may occur in immunosuppressed patients and in elderly persons¹⁵⁰⁻¹⁵³. For this reason, patients on immunosuppressants should be revaccinated with VPP23 a second time within 5 years from the first dose. However, more than one re-vaccination is not recommended since vaccination with pneumococcal polysaccharide antigens may induce hyporesponsiveness and a less robust antibody response may occur on the subsequent doses¹⁵². VPC13 has a conjugated protein in its formulation that is recognized by T-cells, stimulating serum antibody response and immunologic memory. Therefore, revaccination with VPC13 is not indicated. VPC13 also boosts the immunological response to VPP23, stimulates mucosal immunity and decreases nasal and oropharynx colonization¹⁵⁴.

Patients should be vaccinated according to the following schedule (Figure 2)^{138,154,155}:

In patients **who have not been previously vaccinated**, a single dose of VPC13 should be given, followed by a dose of VPP23 at least 8 weeks later. Patients should be revaccinated with VPP23 at least 5 years from the first dose (this second dose can be given either before 65 years old or after).

For individuals **who have already been vaccinated with VPP23**, a single dose of VPC13 should be given 1 or more years after the last dose of VPP23. Revaccination with VPP23 should occur 5 years after the last dose and no sooner than 8 weeks after VPC13.

EFFICACY

In general, pneumococcal vaccination turned out to be as effective in patients with SIRD as in healthy controls. Regarding SLE patients, there are conflicting results, with two studies demonstrating lower efficacy^{92,97} and a shorter seroprotection period (42% of SLE patients lost SP 3 years after immunizations⁹⁷). However, treatment with methotrexate, TNF inhibitors and rituximab is associated with lower efficacy either with




FIGURE 2. Pneumococcal vaccination schedule

Adapted from Froes F, Diniz A, Robalo Cordeiro C, Serrado M, Ramalho de Almeida A. Consensus document for the prevention of respiratory infections in adults. Sociedade Portuguesa de Pneumologia. Rev Port de Pneumologia. 2014;20(2):111-1114

VPP23 or VPC13, as it was demonstrated in three studies involving patients with SpA (including PsA)^{94,106,110} and in seven studies in patients with RA^{93,95,101,103,104,108,112}. Data on tocilizumab (TCZ) and abatacept (ABA) are scarce, with only two studies demonstrating no negative impact in seroprotection in RA patients receiving TCZ^{101,104} and one study showing that ABA reduces the efficacy of VPC13 in RA patients¹⁰⁴. With regard to belimumab, there is only one study available in patients with SLE, showing no immunological impairment after pneumococcal vaccination in patients receiving belimumab⁹¹.

SAFETY

Several studies demonstrate that pneumococcal immunization is safe, with only one study in RA and SpA patients treated with anti-TNF reporting two serious adverse events (pneumonia and soft tissue infection)⁹⁴. Both vaccines appear not to influence disease activity^{96,99,104,107,108}.

(*) Systemic corticotherapy ≥ 20 mg/day prednisolone or equivalent for ≥ 14 days; methotrexate $> 0,4$ mg/Kg/week; azathioprine > 3 mg/Kg/day; leflunomide, mycophenolate, cyclophosphamide, cyclosporine and tacrolimus. Biological therapy or DMARDs used in rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome and inflammatory bowel disease, including anti-TNF (infliximab, etanercept, adalimumab, golimumab, certolizumab); anti-CD20 (rituximab); anti-IL6 (tocilizumab); CTLA-4-Ig (abatacept); anti-BLYS (belimumab); anti-IL12 e anti-IL23 (ustekinumab); IL-1 antagonist (anakinra/canakinumab).

3. HEPATITIS B

a) All SIRD patients with negative serology for hepatitis B virus (HBsAg, AntiHBc, and AntiHBs

negative) should be vaccinated. Level of evidence 2b; Grade of recommendation C.

b) In the case of isolated antiHBc antibody positivity and negative viral load, vaccination should be considered. Level of evidence 5; Grade of recommendation D.

c) The response to vaccination should be assessed 1-2 months after the third dose, and revaccination considered (0, 1 and 6 months) if seroprotection is not achieved. Level of evidence 2b; Grade of recommendation C. Agreement (all statements, mean (SD)): 8.7(1.4).

INDICATIONS

Universal hepatitis B (HB) vaccination is recommended for all Portuguese children and adults, according to the National Vaccination Program (PNV)¹⁵⁸. This has resulted in a great decrease in HB incidence over the past two decades¹⁵⁹. SIRD patients have an increased risk of liver disease due to drug toxicity (synthetic and biologic DMARDs, NSAIDs) and infectious diseases (including acute/chronic HB and reactivation of past HB due to severe immunosuppression).

USE

In order to prevent the development of a potential comorbidity that could seriously interfere with the treatment and outcome of SIRD patients, HB vaccination (3 doses: 0, 1 and 6 months) is recommended for all patients with negative serology (HBsAg, AntiHBc, and AntiHBs negative). One to two months after the third dose of the vaccine (*i.e.* 7-8 months after starting the vaccination scheme), AntiHBs titers should be mea-

sured so as to assess response to vaccination^{113,114,116}. Seroprotection is defined as a serum titer above 10IU/L and, if it is not achieved, revaccination should be considered. Only one study addressed this question in two inactive SLE patients, not on DMARDs, that responded to vaccination only after a 4th dose¹¹³. However, based on expert recommendations, a repetition of the complete 3-dose scheme – 0, 1 and 6 months – should be preferred if patients fail to respond at first.

There is no available evidence concerning the effect of accelerated (0-1-2-12 months) or super accelerated schedules (0-7-21-360 days) of HB vaccination on SIRD patients and, therefore, no recommendations can be issued for these strategies. However, this might be an option if a rapid immune response is needed.

EFFICACY

Despite the limited number of studies available, HB vaccination of SIRD patients was effective in 68-93% of cases^{113,114,116}. Importantly, lower responses were reported in the study where most RA patients were treated with MTX, other sDMARDs and/or glucocorticoids¹¹⁴. There were no data available on the effect of biologics on vaccine efficacy.

SAFETY

There were no reports of safety or disease-worsening issues. Based on these data, on extrapolation from other vaccines and experts' opinion, HB vaccine can and should be administered in every SIRD patient without protective antibodies for HBV. Patients who present isolated positive AntiHBc due to previous contact with HBV may still benefit from vaccination, in order to generate AntiHBs antibodies that can be protective in the event of reexposure. Confirmation of undetectable viral load should be attained prior to immunization.

4. HEPATITIS A

a) Vaccination is recommended for SIRD patients travelling to endemic countries, preferably with 2 doses 6 months apart. Level of evidence 2b; Grade of recommendation B; Agreement: 8.9(1.4).

INDICATIONS

The incidence of hepatitis A (HA) has dramatically decreased in Portugal in the last 20 years due to major improvements in the overall environmental and socioeconomic conditions¹⁵⁹⁻¹⁶¹. Universal HA vaccination is, thus, currently not recommended and is limited to individuals travelling to high prevalence countries (Africa, South and Central America, parts of Asia and Eastern Europe) or during an outbreak of disease^{162,163}. In some patients with liver disease or at high

risk for hepatotoxicity, due to the occurrence of occasional outbreaks of hepatitis A related to contamination of imported foods with hepatitis A virus, immunization should be considered even if travel is not expected^{162,163}. Due to the decrease in the prevalence of HA in Portugal, the number of susceptible younger individuals has risen and this could lead to greater and more frequent outbreaks¹⁶³. Protecting more vulnerable patients through immunization would prevent potentially serious liver disease or worsening of the SIRD due to suspension of hepatotoxic DMARDs.

USE

For SIRD patients, two doses of the vaccine should be administered (0 and 6 months) before travelling, in order to ensure adequate protection¹¹⁵.

EFFICACY AND SAFETY

In a cohort study of 53 RA patients treated with TNF blockers ± MTX, vaccination response was low after the first dose (6-20%), especially in patients exposed to MTX, and greatly increased after the second (82%)¹¹⁵. No adverse events were reported¹¹⁵.

5. PAPILOMAVIRUS

a) Consider HPV vaccine with 3 doses scheme (0, 2 and 6 months) in young adults with SIRD that have not been previously vaccinated. Level of evidence: 2b, Grade of recommendation: C, Agreement (mean (SD)): 8.6(1.7).

INDICATIONS

Quadrivalent human papillomavirus (HPV) vaccine is a recombinant vaccine against HPV serotypes 6, 11, 16 and 18. It is included in the Portuguese National Vaccination Plan and scheduled as a 2-dose series (0 and 2 months) for all girls between 10 to 13 years old; a 3-dose series (0, 2 and 6 months) is used for women between 18 and 25 years old¹⁶⁴. Systemic Lupus Erythematosus (SLE) patients have an increased incidence of human papillomavirus (HPV) infection and cervical dysplasia. HPV clearance is also decreased comparing to the general population^{165,166}. Experts suggest that HPV vaccination should also be extended to males in order to achieve universal immunity.

USE

In the opinion of our taskforce, young adult SIRD patients (both male and female) should be considered for HPV vaccination if not previously immunized.

EFFICACY AND SAFETY

HPV vaccine is safe and effective in SLE patients with stable disease¹²⁰. No evidence is available for other SIRD, but as with other non-live vaccines, HPV vac-

cine is considered safe in immunosuppressed patients (General Recommendation 5).

6. TETANUS

a) Patients with SIRD should follow the recommended vaccination schedule in the National Vaccine Program, i.e. tetanus and diphtheria (Td) every 10 years. Level of evidence 2b, Grade of recommendation B, Agreement (mean (SD)): 9.6(1.0).

INDICATIONS

SIRD patients should follow the National Vaccination Program schedule¹⁶⁸.

EFFICACY

Tetanus toxoid vaccination (TTV) immunogenicity was shown to be reduced in RA and SLE patients comparing to healthy controls, independently of the use of glucocorticoids and immunosuppressants^{123,127,167}. The efficacy of the vaccine when administered 2 weeks after rituximab was similar to methotrexate monotherapy⁶⁶. Nevertheless, as immunogenicity might be decreased within 1-3 months after B-cell depleting therapy, it is recommended to vaccinate patients 4 weeks before initiation of therapy, or alternatively 6-8 months after the last infusion (General Recommendations 2 and 3).

SAFETY

TTV was demonstrated to be safe in RA and SLE patients^{123,127,167}.

7. HERPES ZOSTER

a) In patients with SIRD over 60 years it is recommended individual assessment of the risk/benefit of HZ vaccine. Level of evidence 4, Grade of recommendation D, Agreement (mean (SD)): 8.7(1.7).

INDICATIONS

Herpes zoster (HZ) has an incidence of 34/1000 people-year and will affect 1 in 3 adults. Following natural infection (varicella or chickenpox) or vaccination, varicella zoster viruses (VZV) reside, latent, on the dorsal root ganglia. Over time, reactivation may occur, mainly by changes in cell mediated immunity. The vaccine reduced the risk for developing zoster by 51% and prevented post-herpetic neuralgia (PHN) in 67% persons. In general, with increasing age at vaccination declines the vaccine efficacy, but the vaccine retained efficacy against severity of zoster better than against zoster itself. For persons older than 80 years the efficacy against zoster was 18%, but the efficacy against PHN was 39%¹⁷⁴.

Patients with SIRD have an increased risk for herpes

zoster¹⁶⁹⁻¹⁷³. Immunosuppressed patients have a higher risk of severe rash, visceral dissemination or death, whereby prevention is desirable¹⁷⁵⁻¹⁷⁷. On the other hand, the administration of live vaccines, such as HZ vaccine bears the potential risk of invasive infection in susceptible individuals (General Recommendation 6).

According to the Center of Disease Control and Prevention Advisory Committee on Immunization Practices Recommendations (CDC-ACIP) and the American College of Rheumatology (ACR), herpes zoster vaccination should be considered in patients >60 years-old who are receiving: prednisone <20 mg/day, short term (<2 weeks) corticosteroids, topical or intraarticular corticosteroids, 'low dose' methotrexate (defined as <0.4 mg/kg/week), azathioprine (<3.0 mg/kg/day) or 6-mercaptopurine (<1.5 mg/kg/day). The guidelines do not address vaccine use when these agents are combined. They state the vaccine should not be given in the following circumstances: treatment with biologics (specifically naming adalimumab, infliximab and etanercept); high dose corticosteroids > 20 mg/day for more than two weeks; active leukemia, lymphoma, malignant neoplasm affecting bone marrow or lymphatics; AIDS/HIV patients and those with CD4 lymphocyte counts < 200 per mm³ clinical or laboratory evidence of cellular immunodeficiency (patients with hypogammaglobulinemia or dysgammaglobulinemia can receive the zoster vaccine); hematopoietic stem cell transplantation; pregnancy and severe acute illness.

EFFICACY

In our SLR, we found two large retrospective studies concerning VZV vaccination in SIRD patients, including patients receiving biologics^{118,119}. VZV vaccine (single dose of 0.65mL subcutaneously) was administered to RA, PsA, SpA, psoriasis and inflammatory bowel disease patients treated with TNF inhibitors (n=553), non-TNF biologics (n=82), DMARDs and/or glucocorticoids (average dose 14.02 mg/day, range 2.5-50mg/day). Immunization was associated with a long-term (2 years of follow-up) protective effect^{118,119}.

SAFETY

HZV was not associated with an increase of HZV infections up to 42 days after vaccination (95%CI - 0-5.4 cases per 1000 anti-TNF users and 0-4.7 per 1000 biologic users)^{118,119}. The vaccine also appears to be safe and well tolerated by SLE patients, but reduced effectiveness is a concern¹¹⁷.

USE

In light of the available evidence, our taskforce con-

TABLE III. SUMMARIZED INFORMATION ON VACCINES, RECOMMENDED USE AND DOSING SCHEMES

Vaccine	Type	Use	Dosing schemes
Non-live vaccines			
Influenza	Inactivated	All SIRD patients ^a	Yearly administration
Pneumococcal - VPC13 ^b	Conjugate	All SIRD patients ^a	Single dose (If previous PPSV23 vaccination, >1 year (y) interval is recommended)
Pneumococcal – PPSV23 ^c	Inactivated	All SIRD patients ^a	First dose: ≥8 weeks after VPC13 Second dose: 5 y after 1 st
Hepatitis B	Subunit	Negative serology for Hep B <i>or</i> Isolated antiHBc antibody positivity and negative viral load	Dosing: 0, 1 and 6 months ^h (mo) Assess Ac. Anti-Hbs titer 1-2 mo after the last dose Revaccinate if titer <10 IU/L
Hepatitis A	Inactivated	Susceptible travellers to endemic regions	0 and 6 mo ^h
Papillomavirus	Subunit	Young adults (female or male) not previously vaccinated	0, 2 and 6 mo
Tetanus/diphtheria ^d	Toxoid	All SIRD patients ^a	Every 10 y
Poliomyelitis (parenteral) ^d	Inactivated	Unvaccinated or incompletely vaccinated patients	Scheme: 0, 1 and 6-12 mo. Single booster ≥10y after scheme completion
Live attenuated viral vaccines (LAVV)^e			
Varicella	LAVV	Susceptible persons (negative anti-VZV)	Dosing: 0 and 4 weeks
Varicella zoster (herpes zoster)	LAVV	SIRD patients ≥60 yo. ⁱ	Single dose
MMR ^{d,f}	LAVV	Selected SIRD patients ^d	Single dose
Yellow fever ^g	LAVV	Travelers to endemic regions	Single dose

a. Ideally ≥4 weeks before any immunosuppressive treatment or ≥6 months after rituximab, controlled disease activity is advised; b. VPC13: 13-valent Pneumococcal conjugate vaccine; c. PPSV23: 23-valent Pneumococcal polysaccharide vaccine; d. SIRD patients should comply with the National Vaccination Program recommendations for adults ≥18 yo; e. The administration of live vaccines must be based in an individual assessment of the risk/benefit, which includes disease activity, medication, the replication potential of the vaccine and the risk of infection; f. MMR: measles, mumps, rubella; g. Previous consultation with a Traveller's Medicine Specialist is recommended; h. Accelerated (0-1-2-12 months) or super accelerated schedules (0-7-21-360 days) of HB vaccination can be used for people travelling on short notice that face imminent exposure or for emergency responders to disaster areas. A combined hepatitis A and hepatitis B vaccine can also be used on the same 3-dose schedule (0, 7, and 21–30 days), with a booster at 12 months. However, these vaccination schemes have not been tested in SIRD patients; i. Receiving prednisone <20 mg/day, short term (<2 weeks) corticosteroids, topical or intraarticular corticosteroids, 'low dose' methotrexate (defined as <0.4 mg/kg/week), azathioprine (<3.0 mg/kg/day) or 6-mercaptopurine (<1.5 mg/kg/day).

sidered that the risk/benefit of the HZV must be individually assessed, including patient age, disease activity, medication and the risk of infection.

Table III summarizes information on review vaccines, such as type of vaccine, recommended use and dosing schemes.

CONCLUSIONS

Thirteen evidence-based recommendations for vaccination in adult patients with SIRD were elaborated ai-

ming to improve care for these patients.

The present recommendations combine scientific evidence with the expertise of a multidisciplinary panel and attaining desirable agreement among Portuguese rheumatologists. For dissemination purposes, the current paper will be published in a MEDLINE-indexed journal and will be freely available online at the SPR website. SPR members will be notified by email and/or newsletter after publication. However, there are still many areas deserving future research (Table IV). Most studies used surrogate markers of efficacy, such as seroprotection and seroconversion, instead of the oc-

TABLE IV. AREAS OF FUTURE RESEARCH

Areas of future research	
Live vaccines	Safety and efficacy on the context of ongoing immunosuppression;
Herpes Zoster Vaccine	A more permissive guideline might be issued if favourable safety, efficacy and cost/benefit relation could be established;
Meningococcal (trivalent and serotype B) vaccines	No published data could be found until December 2014;
Primary systemic vasculitis and connective tissue diseases other than SLE and RA	The impact of disease activity and treatment in the safety and efficacy of vaccination;
Rituximab, tocilizumab, abatacept, belimumab, ustekinumab, secukinumab and kinase-targeted sDMARDs	The immunogenicity and safety of vaccinations in SIRD patients under such therapies;
Hepatitis B	The role of booster vs. revaccination in rituximab-treated patients whose AntiHBs titers decline after one or more infusions.

currence of infections as the primary study outcome. Definite conclusions on the impact of disease activity or immunosuppressive drugs on the safety of vaccination were limited by variability in the measures used in the assessments. Evidence was also scarce on various other contexts (Table IV).

The reader of these recommendations should keep in mind that many recommendations given in this article are based on clinical experience and expert opinion as scientific data are still scarce on many aspects.

Vaccination recommendations need to be updated on a regular basis, as more scientific data regarding vaccination efficacy and safety, emergent infectious threats, new vaccines as well as new immunomodulators become available.

ACKNOWLEDGEMENTS

We would like to thank Senior Librarian Prof. Helena Donato for her support in the development of the search strategy.

DISCLOSURES AND FUNDING

This initiative received financial and logistic support by Sanofi-Pasteur MSD®; bibliographic support was provided by AbbVie®.

This article was originally published in *Acta Reumatol Port.* 2016; 41:112-130.

REFERENCES

- Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. *Clin Rheumatol.* 2007; 26: 663–670.
- Bosch X, Guilabert A, Pallarés L, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. *Lupus.* 2006; 15: 584–589.
- Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum.* 2002; 46: 2287–2293.
- Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. *Arthritis Rheum* 1994; 37: 481–494.
- Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine (Baltimore).* 2003; 82: 299–308.
- Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. *Ann Rheum Dis.* 2007; 66: 940–944.
- Ruangjutipopan S, Kasitanon N, Louthrenoo W, et al. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. *J Med Assoc Thai.* 2002; 85: 1204–1209.
- Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992; 116: 488–498.
- Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. *Arthritis Rheum* 2000; 43: 1021–1032.
- Marie I, Hachulla E, Chérin P, et al. Opportunistic infections in poly-myositis and dermatomyositis. *Arthritis Rheum* 2005; 53: 155–165.
- Ho TY, Huang KY, Huang TT, et al. The impact of influenza vaccinations on the adverse effects and hospitalization rate in the elderly: a national based study in an Asian country. *PLoS One.* 2012; 7: e50337. doi: 10.1371/journal.pone.0050337. Epub 2012 Nov 28.
- Wörns MA, Teufel A, Kanzler S, et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. *Am J Gastroenterol.* 2008; 103: 138–146. Epub 2007 Oct 26.
- Feuchtenberger M, Kleinert S, Schwab S, et al. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. *Rheumatol Int.* 2012; 32: 1533–1539. doi: 10.1007/s00296-011-1808-z. Epub 2011 Feb 15.
- Lanternier F, Henegar C, Mouthon L, Blanche P, Guillevin L, Launay O. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. *Ann Rheum Dis.* 2008; 67: 1047. doi: 10.1136/ard.2007.081703.
- Ledwich LJ, Harrington TM, Ayoub WT, Sartorius JA, Newman ED. Improved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert. *Arthritis Rheum.* 2009; 61: 1505–1510. doi: 10.1002/art.24873.
- McCarthy EM, Azeez MA, Fitzpatrick FM, Donnelly S. Knowledge, attitudes, and clinical practice of rheumatologists in vaccination of the at-risk rheumatology patient population. *J Clin Rheumatol.* 2012; 18: 237–241. doi: 10.1097/RHU.0b013e3182611547.
- McCarthy EM, de Barra E, Bergin C, Cunnane G, Doran M. Influenza and pneumococcal vaccination and varicella status in inflammatory arthritis patients. *Ir Med J.* 2011; 104: 208–211.
- Mouthon L, Mestre C, Bérezné A, et al. Low influenza vaccination rate

- among patients with systemic sclerosis. *Rheumatology (Oxford)*. 2010; 49: 600-606. doi: 10.1093/rheumatology/kep440. Epub 2009 Dec 29.
19. Sowden E, Mitchell WS. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. *BMC Musculoskelet Disord*. 2007; 8: 58.
 20. Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. *Rheumatol Int*. 2014; 34: 151-163.
 21. Groot N, Heijstek MW, Wulfraat NM. Vaccinations in paediatric rheumatology: an update on current developments. *Curr Rheumatol Rep*. 2015; 17: 46.
 22. Van Assen S, Agmon-Levin N, Elkayam O et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis*. 2011; 70: 414-422.
 23. Brenol CV, da Mota LM, Cruz BA et al. 2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis. *Rev Bras Reumatol*. 2013; 53: 4-23.
 24. Kwok WY, Plevier JW, Rosendaal FR, Huizinga TW, Kloppenburg M. Risk factors for progression in hand osteoarthritis: a systematic review. *Arthritis Care Res (Hoboken)*. 2013; 65: 552-562. doi: 10.1002/acr.21851.
 25. Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org.
 26. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. *Ann Rheum Dis*. 2006; 65: 191-194. Epub 2005 Jul 13.
 27. França IL, Ribeiro AC, Aikawa NE, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. *Rheumatology (Oxford)*. 2012; 51: 2091-2098. doi: 10.1093/rheumatology/kes202. Epub 2012 Aug 20.
 28. Francioni C, Rosi P, Fioravanti A, Megale F, Pipitone N, Marcolongo R. Vaccination against influenza in patients with rheumatoid arthritis: clinical and antibody response. *Recenti Prog Med*. 1996; 87: 145-149.
 29. Gabay C, Bel M, Combescurc C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. *Arthritis Rheum*. 2011; 63: 1486-1496. doi: 10.1002/art.30325.
 30. Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. *Arthritis Rheum*. 2011; 63: 1486-1496. doi: 10.1002/art.30325.
 31. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumor necrosis factor treatment on the antibody response to influenza vaccination. *Ann Rheum Dis*. 2008; 67: 713-716. Holvast A, de Haan A, van Assen S, et al. Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis. *Ann Rheum Dis*. 2010; 69: 924-927. doi: 10.1136/ard.2009.112813.
 32. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. *Ann Rheum Dis*. 2006; 65: 913-918.
 33. Holvast A, Stegeman CA, Benne CA, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. *Ann Rheum Dis*. 2009; 68: 873-8778.
 34. Holvast A, van Assen S, de Haan A, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. *Arthritis Rheum*. 2009; 60: 2438-2447.
 35. Iwamoto M, Homma S, Onishi S, et al. Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. *Rheumatol Int*. 2012; 32: 3691-3694.
 36. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. *Rheumatology (Oxford)*. 2007; 46: 608-611.
 37. Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. *Scand J Rheumatol*. 2013; 42: 445-450. doi: 10.3109/03009742.2013.788733.
 38. Kobie JJ, Zheng B, Bryk P, et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. *Arthritis Res Ther*. 2011; 13: R209. doi: 10.1186/ar3542.
 39. Kostianovsky A, Charles P, Alves JF, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. *Clin Exp Rheumatol*. 2012; 30: 83-89.
 40. Kubota T, Nii T, Nanki T, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. *Mod Rheumatol*. 2007; 17: 531-533.
 41. Launay O, Paul S, Servettaz A, et al. Control of humoral immunity and auto-immunity by the CXCR4/CXCL12 axis in lupus patients following influenza vaccine. *Vaccine*. 2013; 31: 3492-3501. doi: 10.1016/j.vaccine.2013.05.095. Epub 2013 Jun 11.
 42. Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Mörner A, Geborek P. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. *Arthritis Res Ther*. 2014; 16: R2.
 43. Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. *Ann Intern Med*. 1978; 88: 790-2.
 44. Ristow SC, Douglas RG Jr, Condem JJ. Influenza vaccination of patients with systemic lupus erythematosus. *Ann Intern Med*. 1978; 88: 786-789.
 45. Mercado U, Acosta H, Avendaño L. Influenza vaccination of patients with systemic lupus erythematosus. *Rev Invest Clin*. 2004; 56: 16-20.
 46. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. *Ann Rheum Dis*. 2008; 67: 937-941. Epub 2007 Nov 2.
 47. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNF alpha blockers: safety and immunogenicity. *Clin Immunol*. 2010; 134: 113-120. doi: 10.1016/j.clim.2009.09.014. Epub 2009 Oct 21.
 48. Lu CC, Wang YC, Lai JH, Lee TS, Lin HT, Chang DM. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. *Vaccine*. 2011; 29: 444-450. doi: 10.1016/j.vaccine.2010.10.081. Epub 2010 Nov 13.
 49. Mathian A, Devilliers H, Krivine A, et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. *Arthritis Rheum*. 2011; 63: 3502-3511. doi: 10.1002/art.30576.
 50. Miraglia JL, Abdala E, Hoff PM, et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. *PLoS One*. 2011; 6: e27214. doi: 10.1371/journal.pone.0027214. Epub 2011 Nov 8.
 51. Ribeiro AC, Guedes LK, Moraes JC, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. *Ann Rheum Dis*. 2011; 70: 2144-2147. doi: 10.1136/ard.2011.152983. Epub 2011 Aug 22.
 52. Saad CG, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. *Ann Rheum Dis*. 2011; 70: 1068-1073. doi: 10.1136/ard.2011.152050.
 53. Litinsky I, Balbir A, Zisman D, et al. Vaccination against influenza in patients with systemic sclerosis. *Clin Exp Rheumatol*. 2012; 30: 7-11. Epub 2012 May 29.
 54. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2012; 71: 2006-2010. doi: 10.1136/annrheumdis-2012-201950. Epub 2012 Aug 11.
 55. Perdan-Pirkmajer K, Thallinger GG, Snoj N, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. *Lupus*. 2012; 21: 175-183. doi: 10.1177/0961203311429817.
 56. Milanovic M, Stojanovich L, Djokovic A, Kontic M, Gvozdenovic E. Influenza vaccination in autoimmune rheumatic disease patients. *Tohoku J Exp Med*. 2013; 229: 29-34.
 57. Miossi R, Fuller R, Moraes JC, et al. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. *Clinics (Sao Paulo)*. 2013; 68: 129-134.
 58. Pasoto SG, Ribeiro AC, Viana VS. Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical mani-

- festations and autoantibody profile in primary Sjögren's syndrome. *Vaccine*. 2013; 31: 1793-1798. doi: 10.1016/j.vaccine.2013.01.057. Epub 2013 Feb 7.
59. Ribeiro AC, Laurindo IM, Guedes LK, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2013; 65: 476-480. doi: 10.1002/acr.21838.
 60. Milanetti F, Germano V, Nisini R, et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. *Clin Exp Immunol*. 2014; 177: 287-294. doi: 10.1111/cei.12292.
 61. Abu-Shakra M, Press J, Sukenik S, Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. *Clin Rheumatol*. 2002; 21: 369-372.
 62. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. *J Rheumatol*. 2002; 29: 2555-2557.
 63. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. *J Rheumatol*. 2000; 27: 1681-1685.
 64. Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study. *Rheumatology (Oxford)*. 2012; 51: 695-700. doi: 10.1093/rheumatology/ker389. Epub 2011 Dec 14.
 65. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. *Vaccine*. 2011; 29: 1643-1648. doi: 10.1016/j.vaccine.2010.12.072. Epub 2011 Jan 4.
 66. Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. *Arthritis Rheum*. 2010; 62: 64-74. doi: 10.1002/art.25034.
 67. Bridges MJ, Coady D, Kelly CA, Hamilton J, Heycock C. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2003; 62: 685.
 68. Brodman R, Gilfillan R, Glass D, Schur PH. Influenza vaccine response in systemic lupus erythematosus. *Ann Intern Med*. 1978; 88: 735-740.
 69. Borba EF, Saad CG, Pasoto SG, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? *Rheumatology (Oxford)*. 2012; 51: 1061-1069. doi: 10.1093/rheumatology/ker427. Epub 2012 Jan 31.
 70. Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. *J Rheumatol*. 1994; 21: 1203-1206.
 71. Crowe SR, Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. *Arthritis Rheum*. 2011; 63: 2396-2406. doi: 10.1002/art.30388.
 72. Del Porto F, Laganà B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. *Vaccine*. 2006; 24: 3217-3223. Epub 2006 Jan 23.
 73. Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. *Arthritis Care Res (Hoboken)*. 2011; 63: 1062-1067. doi: 10.1002/acr.20465.
 74. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. *Semin Arthritis Rheum*. 2010; 39: 442-447. doi: 10.1016/j.semarthrit.2008.12.002. Epub 2009 Feb 26.
 75. Kogure T, Harada N, Tatsumi T, Fujinaga H. Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis. *Clin Rheumatol*. 2014; 33: 323-328. doi: 10.1007/s10067-013-2483-0. Epub 2014 Jan 21.
 76. Setti M, Fenoglio D, Ansaldo F, et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. *Vaccine*. 2009; 27: 3367-3372. doi: 10.1016/j.vaccine.2009.01.078. Epub 2009 Feb 5.
 77. Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus and rheumatoid arthritis. *Clin Dev Immunol*. 2006; 13: 373-5.
 78. Tarján P, Sipka S, Lakos G, Kiss E, Ujj G, Szegedi G. Influenza vaccination and the production of anti-phospholipid antibodies in patients with systemic lupus erythematosus. *Scand J Rheumatol*. 2006; 35: 241-243.
 79. Urowitz MB, Anton A, Ibanez D, Gladman DD. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*. 2011; 63: 1517-1520. doi: 10.1002/acr.20599.
 80. Wallin L, Quintilio W, Locatelli F, Cassel A, Silva MB, Skare TL. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. *Acta Reumatol Port*. 2009; 34: 498-502.
 81. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. Influenza immunization in systemic lupus erythematosus. A double-blind trial. *Ann Intern Med*. 1978; 88: 729-734.
 82. Zycinska K, Romanowska M, Nowak I, Rybicka K, Wardyn KA, Brydak LB. Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis. *J Physiol Pharmacol*. 2007; 58: 819-828.
 83. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. *Arthritis Rheum*. 2010; 62: 75-81. doi: 10.1002/art.25033.
 84. Kogure T, Harada N, Oku Y, Tatsumi T, Niizawa A. The observation of humoral responses after influenza vaccination in patients with rheumatoid arthritis treated with Japanese oriental (kampo) medicine: an observational study. *Evid Based Complement Alternat Med*. 2012; 2012: 320542. doi: 10.1155/2012/320542. Epub 2012 Apr 22.
 85. Westra J, van Assen S, Wiltink KR, Land J, Horst G, de Haan A, Bijl M. Rituximab impairs immunoglobulin (IgM and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. *Clin Exp Immunol*. 2014; 178: 40-47. doi: 10.1111/cei.12390.
 86. de Medeiros DM, Silva CA, Bueno C, et al. Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production? *Lupus*. 2014; 23: 1412-1416. doi: 10.1177/0961203314540351. Epub 2014 Jun 24.
 87. Wiesik-Szewczyk E, Romanowska M, Mielnik P, et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. *Clin Rheumatol*. 2010; 29: 605-613. doi: 10.1007/s10067-010-1373-y. Epub 2010 Feb 7.
 88. Muller RB, Maier R, Hoshler K, et al. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. *Clin Exp Rheumatol*. 2013; 31: 723-730. Epub 2013 Jun 14.
 89. Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE. Rituximab-treated patients have a poor response to influenza vaccination. *J Clin Immunol*. 2013; 33: 388-396. doi: 10.1007/s10875-012-9813-x. Epub 2012 Oct 14.
 90. Vista ES, Crowe SR, Thompson LF, Air GM, Robertson JM, Guthridge JM, James JA. Influenza vaccination can induce new-onset anticardiolipins but not beta2-glycoprotein-I antibodies among patients with systemic lupus erythematosus. *Lupus*. 2012; 21: 168-174. doi: 10.1177/0961203311429554.
 91. Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. *J Rheumatol*. 2012; 39: 1632-1640. Epub 2012 Jun 15.
 92. Jarrett MP, Schiffman G, Barland P, Grayzel AI. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. *Arthritis Rheum*. 1980; 23: 1287-1293.
 93. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. *Clin Rheumatol*. 2011; 30: 1555-1561. doi: 10.1007/s10067-011-1856-5. Epub 2011 Sep 29.
 94. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. *Arthritis Rheum*. 2011; 63: 3723-3732. doi: 10.1002/art.30580.
 95. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients

- with rheumatoid arthritis. *Rheumatology (Oxford)*. 2006; 45: 106-111. Epub 2005 Nov 15.
96. Karsh J, Pavlidis N, Schiffman G, Moutsopoulos HM. Immunization of patients with Sjögren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. *Arthritis Rheum*. 1980; 23: 1294-1248.
 97. Klippel JH, Karsh J, Stahl NI, Decker JL, Steinberg AD, Schiffman G. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. *Arthritis Rheum*. 1979; 22: 1321-1325.
 98. McDonald E, Jarrett MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. *J Rheumatol*. 1984; 11: 306-308.
 99. Lipnick RN, Karsh J, Stahl NI, Blackwelder WC, Schiffman G, Klippel JH. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. *J Rheumatol*. 1985; 12: 1118-1121.
 100. Pisoni C, Sarano J, Benchetrit G, et al. Antipneumococcal vaccination in patient with systemic lupus erythematosus. *Medicina (B Aires)*. 2003; 63: 388-392.
 101. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. *Ann Rheum Dis*. 2013; 72: 1362-1366. doi: 10.1136/annrheumdis-2012-202658. Epub 2013 Jan 23.
 102. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2012; 71: 2006-2010. doi: 10.1136/annrheumdis-2012-201950. Epub 2012 Aug 11.
 103. Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. *Ann Rheum Dis*. 2011; 70: 1289-1291. doi: 10.1136/ard.2010.144451. Epub 2011 Apr 22.
 104. Crnkic-Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2013; 15: R171. doi: 10.1186/ar4358.
 105. Croft SM, Schiffman G, Snyder E, Herrmann K, James K, Jarrett MP. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus. *J Rheumatol*. 1984; 11: 141-146.
 106. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. *Semin Arthritis Rheum*. 2004; 33: 283-238.
 107. Elkayam O, Paran D, Burke M, et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. *Autoimmunity*. 2005; 38: 493-496.
 108. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. *Clin Infect Dis*. 2002; 34: 147-153. Epub 2001 Dec 4.
 109. O Dell JR, Gilg J, Palmer W, Haire C, Klassen L, Moore G. Pneumococcal vaccine in rheumatoid arthritis. *J Clin Rheumatol*. 1996; 2: 59-63.
 110. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. *J Rheumatol*. 2004; 31: 1356-1361.
 111. Tarján P, Sipka S, Maródi L, et al. No short-term immunological effects of Pneumococcus vaccination in patients with systemic lupus erythematosus. *Scand J Rheumatol*. 2002; 31: 211-215.
 112. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. *J Rheumatol*. 2007; 34: 952-957. Epub 2007 Apr 15.
 113. Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfá E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. *Lupus*. 2007; 16: 350-354.
 114. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2002; 61: 623-625.
 115. Askling HH, Rombo L, van Vollenhoven R, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. *Travel Med Infect Dis*. 2014; 12: 134-142. doi: 10.1016/j.tmaid.2014.01.005. Epub 2014 Jan 29.
 116. Erkek E, Ayaslioglu E, Erkek AB, Kurtipek GS, Bagci Y. Response to vaccination against hepatitis B in patients with Behcet's disease. *J Gastroenterol Hepatol*. 2005; 20: 1508-1511.
 117. Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. *J Rheumatol*. 2013; 40: 1875-1880. doi: 10.3899/jrheum.130170. Epub 2013 Sep 15.
 118. Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. *Arthritis Res Ther*. 2011; 13: R174. doi: 10.1186/ar3497. Epub 2011 Oct 24.
 119. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. *JAMA*. 2012; 308: 43-49. doi: 10.1001/jama.2012.7304.
 120. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. *Ann Rheum Dis*. 2013; 72: 659-664. doi: 10.1136/annrheumdis-2012-201393. Epub 2012 May 15.
 121. Schattner A, Ben-Chetrit E, Schmilovitz H. Poliovaccines and the course of systemic lupus erythematosus—a retrospective study of 73 patients. *Vaccine*. 1992; 10: 98-100.
 122. Devvey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. *Clin Exp Immunol*. 1987; 68: 562-569.
 123. Scheinberg M, Guedes-Barbosa LS, Manguera C, et al. Yellow fever re-vaccination during infliximab therapy. *Arthritis Care Res (Hoboken)*. 2010; 62: 896-898. doi: 10.1002/acr.20045.
 124. Howick J, Chalmers I, Glasziou P, et al. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. 2011. Available at: <http://www.cebm.net/index.aspx?o=5653>
 125. McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk—what is the evidence?. *Rheumatology* 2009;48: 867-871.
 126. Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. *Lupus*. 2013; 22: 1286-1294.
 127. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. *Arthritis Rheum*. 1998; 41: 1828-1834.
 128. Kaufman I, Moscovici YB, Abudi Y, et al. The effect of infliximab on antiviral antibody profiles in patients with rheumatoid arthritis. *Rheumatol Int*. 2010; 30: 325-329. doi: 10.1007/s00296-009-0959-7. Epub 2009 May 20.
 129. Rehnberg M, Brissler M, Amu S, Zendjanchi K, Håwi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. *Arthritis Res Ther*. 2010;12:R111.
 130. Hugle T, Bircher A, Walker UA. Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. *Rheumatology (Oxford)*. 2012; 51: 761-762. Epub 2011/12/14.
 131. Kotton CN, Freedman DO. Immunocompromised Travelers. In: Centers for Disease Control and Prevention. CDC Health Information for International Travel 2016. New York: Oxford University Press; 2016.
 132. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. *Autoimmun Rev*. 2011; 10: 341-352.
 133. Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. *Rheumatol Int*. 2014; 34: 151-163.
 134. Buhler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. *Swiss medical weekly*. 2015; 145: w14159.
 135. Levin MJ, Song LY, Fenton T et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. *Vaccine* 26(33), 4210-4217 (2008).
 136. Weinberg A, Song LY, Walker R et al. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. *J. Acquir. Im-*

- mune Defic. Syndr. 55(2), 189–196 (2010).
137. Launay O, Guillevin L, Mouthon L. Immunizations in adult patients with systemic sclerosis. *Ann N Y Acad Sci.* 2009;1173:610–618.
 138. Norma da Direção Geral da Saúde nº 011/2015 de 23/06/2015. Available at: <http://www.dgs.pt/directrizes-da-dgs/normas-e-circulares-normativas/norma-n-0112015-de-23062015-pdf.aspx>.
 139. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. *JAMA.* 1999;281:908-913.
 140. Buckley RH, Ballas Z, Ballow M, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts: Medical Advisory Committee of the Immune Deficiency Foundation. *J Allergy Clin Immunol.* 2014; 133:961-966.
 141. McMahan ZH, Bingham CO 3rd. Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. *Arthritis Res Ther.* 2014; 16: 506.
 142. Avery RK. Vaccination of the immunosuppressed adult patient with rheumatologic disease. *Rheum Dis Clin North Am.* 1999; 25: 567-584.
 143. Duchet-Niedziolka P, Coutsinos Z, Hanslik T, Launay O. Anti-TNF alpha therapy and vaccination of adults. *Joint Bone Spine.* 2007; 74: 563-565.
 144. Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF- antagonists. *J Transl Med.* 2014; 12: 77.
 145. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2011; 70: 785-791.
 146. Navarro-Zarza JE, Alvarez-Hernández E, Casasola-Vargas JC, Estrada-Castro E, Burgos-Vargas R. Prevalence of community-acquired and nosocomial infections in hospitalized patients with systemic lupus erythematosus. *Lupus.* 2010; 19: 43-48.
 147. European Centre for Disease Prevention and Control. Influenza Vaccination (online). Last updated [date unknown], cited Sep 13 2015. Available at: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx#sthash.V6Xh8rge.dpuf
 148. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. *JAMA.* 2001; 285: 1729-1735.
 149. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered and clinical outcome. *Clin Infect Dis.* 2003; 37: 230-237.
 150. Fernández-Guerrero ML, Ramos JM, Marrero J, Cuenca M, Fernández-Roblas R, de Górgolas M. Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality. *Int J Infect Dis.* 2003; 7: 46-52.
 151. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. *Cochrane Database Syst Rev.* 2013; 1: CD000422. Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? *Respir Med.* 2011;105:1776-83.
 152. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaptation of the species. *Int J Antimicrob Agents.* 2008; 32: 199-206. doi: 10.1016/j.ijantimicag.2008.01.021. Epub 2008 Apr 18.
 153. Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. *Vaccine.* 2012; 30: 4435-4444. doi: 10.1016/j.vaccine.2012.04.052. Epub 2012 Apr 26.
 154. Center for Disease Control and Prevention. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR.* 2004; 46: 1-24
 155. Froes F, Diniz A, Robalo-Cordeiro C, Serrado M, Ramalho-de-Almeida A. Consensus document for the prevention of respiratory infections in adults. Sociedade Portuguesa de Pneumologia. *Rev Port de Pneumologia.* 2014; 20: 111-114
 156. Center for Disease Control and Prevention. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR.* 2012; 61: 816-819.
 157. Sociedad Española de Medicina Preventiva Salud Pública e Higiene. Recomendaciones de Vacunación Antineumocócica en el adulto por Indicación Médica. 2012; 1-33
 158. George F. Norma da Direção Geral de Saúde nº 040/2011 de 21/12/2011, atualizada em 26/01/2012. Available at: <https://www.dgs.pt/directrizes-da-dgs/normas-e-circulares-normativas/norma-n-0402011-de-21122011-atualizada-a-26012012-jpg.aspx>.
 159. Doenças de declaração obrigatória: casos notificados 1990-2013. Instituto Nacional de Estatística, Direção Geral de Saúde. Available at: <http://www.pordata.pt/Portugal/Doen%C3%A7as+de+declara%C3%A7%C3%A3o+obrigat%C3%B3ria+casos+notificados-773>
 160. Antunes H, Macedo M, Estrada A. Prevalência do vírus da hepatite A: Primeiros resultados de baixa endemicidade em Portugal. *Acta Med Port.* 2004; 17: 219–224.
 161. Marinho RT, Valente A, Ramalho F, Moura MC. Hepatite A: alteração do padrão epidemiológico? *Rev Port Clin Geral* 2000; 16: 103–111.
 162. Antunes H, Cunha F. Recomendações para a vacinação contra o vírus da hepatite A - Secções de Infeciologia e de Gastroenterologia e Nutrição Pediátrica da Sociedade Portuguesa de Pediatria. *Acta Pediátrica Port.* 2007; 38: 268–270.
 163. Marinho RT, Lavanchy T, on behalf of the Viral Hepatitis Prevention Board. Burden and Prevention of Viral Hepatitis in Portugal. *VHPB Newsletter* 2011; 19: 1-24.
 164. Direção-Geral da Saúde. Norma nº 016/2014 de 29/09/2014. Available at: https://www.google.pt/url?sa=t&trct=j&q=&resrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CB8QFjAAhUKEWj4fBR0oPIAHUgRcQKHZAzCIE&url=https%3A%2F%2Fwww.dgs.pt%2Fdi-retrizes-da-dgs%2Fnormas-e-circulares-normativas%2Fnorma-n-0162014-de-29092014.asp&x&usq=AFQjCNFkUZgDdPBM_j1POzc_Ct2oo953cA&sig2=sNUWcb1FS922UCIMbIH0BA
 165. Santana IU, Gomes-Ado N, Lyrio LD, Rios-Grassi MF, Santiago MB. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. *Clin Rheumatol.* 2011; 30: 665-672.
 166. Tam LS, Chan PK, Ho SC, et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study. *J Rheumatol.* 2010; 37: 330-340.
 167. Denman EJ, Denman AM, Greenwood BM, Gall D, Heath RB. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. *Ann Rheum Dis.* 1970; 29: 220-231.
 168. Leça A, Freitas MG, Valente PM. Programa Nacional de Vacinação 2012. In: DGS, editor. Lisboa 2012.
 169. Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. *Lupus.* 2013; 22:238-244.
 170. Zhang N, Wilkinson S, Riaz M, Ostor AJ, Nisar MK. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. *Clin Exp Rheumatol.* 2012; 30: 962-971.
 171. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. *Rheumatology (Oxford).* 2006; 45: 1370-1375.
 172. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. *JAMA.* 2009; 301: 737-744.
 173. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. *Arthritis Rheum.* 2007; 57: 1431-1438.
 174. Merck. Zostavax package insert, 2006. http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf. Accessed in November 24th 2015.
 175. Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. *N Engl J Med.* 1986; 314: 208-212.
 176. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. *MMWR Morbidity and mortality weekly report.* 2014; 63: 729-731.
 177. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control.* 2008; 57: 1-30; quiz CE2-4.

APPENDIX I – QUALITY ASSESSMENT OF VACCINATION STUDIES

DEFINITION OF STUDY POPULATION:

1. Sufficient description of characteristics of study groups

A '1' is given when a paper describes at least setting and time period of the study, ages of patients (and its range), sex and ongoing medication

2. Definition of diagnosis:

Rheumatic disease diagnosis

diagnosis was according accepted classification criteria.

3. Selection bias:

Clear description of selection of study subjects.

When a paper described how the study subjects were selected (description of in- and exclusion criteria) from the population level to the study level, a '1' will be given.

4. Follow-up:

Follow-up time \geq 6 weeks for rheumatic disease patients.

6 weeks was seen as an acceptable follow-up duration to assess antibody production

5. Organization of follow-up

A '1' was given if there was a structured follow-up applied (efficacy and safety). So not only on patients request.

6. Participation rate \geq 80% for study groups

80% was an arbitrary margin chosen to determine the quality of the selection of study subjects.

7. No differences in lost to follow-up (in both groups)

Including (quantitative and qualitative) information on completers and non-completers

8. Assessment of the outcome:

Valid measures of vaccine efficacy Reliable assays used for antibody titer measurement;

Immunologic outcome assessment was blinded to clinical data (at least treatment and symptom duration)

A '1' is given if the observers were blinded to the intervention

9. Safety assessment was performed using valid measures

For example A '1' is given if disease flare was according to accepted definitions

Analysis and Data Presentation

10. Frequencies of most important comorbidities were given

11. Immunosuppressant medication use and dosage was given

12. Frequencies of important outcomes studied were given

13. Appropriate analysis techniques with estimates were used

TOTAL QUALITY RATE (x/13)

Adapted from: Kwok WY, Plevier JW, Rosendaal FR, Huizinga TW, Kloppenburg M. Risk factors for progression in hand osteoarthritis: a systematic review. *Arthritis Care Res (Hoboken)*. 2013;65:552-562.